Jakafi is a medication prescribed to treat certain blood disorders. It is indicated for myelofibrosis, a rare bone marrow disorder, and polycythemia vera, a condition characterized by the overproduction of red blood cells. Myelofibrosis is a chronic condition where the bone marrow is replaced by fibrous tissue, disrupting the production of blood cells. Polycythemia vera involves an abnormal increase in the production of red blood cells, which can cause complications such as blood clots. Jakafi works by inhibiting specific enzymes called Janus kinases, which are involved in the abnormal signaling pathways associated with these blood disorders. By targeting these enzymes, Jakafi helps to reduce symptoms such as enlarged spleen, anemia, and constitutional symptoms, improving the overall quality of life. Fact Table Formula C17H18N6 License EU EMA Bioavailability 95% Legal status Rx-Only Chemical Name Ruxolitinib Elimination half-life 2.8-3 hours Dosage (Strength) 5mg, 15mg, 20mg Pregnancy Consult Doctor Brands Jakafi Protein binding 97% PubChem CID 25126798 MedlinePlus a612006 ChEBI 66919 ATC code L01EJ01 DrugBank DB08877 KEGG D09959 Routes of administration By mouth